An accelerated rebound in medical device sales helped drive Johnson & Johnson (NYSE:JNJ) second-quarter results that topped the consensus forecast.
The New Brunswick, N.J.-based company posted profits of $6.3 billion, or $2.35 per share, on sales of $23.3 billion for the three months ended June 30, 2021, for a 73.1% bottom-line gain on sales growth of 27.1% year-over-year.
Get the full story at our sister site, MassDevice.
Filed Under: Drug Discovery, Drug Discovery and Development
